Fatima Rodriguez, MD
Cardiovascular Disease · Stanford, CANPI 1184918393
Payments from drug & device makers
Across 189 payments — averaging $1224.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk AS$93K
- Novartis$46K
- Heartflow, Inc.$38K
- Edwards Lifesciences$15K
- Janssen Global Services, LLC$15K
- Amgen$10K
- plus $15K from 7 others
Across 104 payments — averaging $2184.18 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novo Nordisk AS$174K
- Novartis$26K
- Cleerly, Inc.$23K
- Regeneron$2K
- Amgen$2K
What the payments were for
- Consulting fees$126,40891%
- Speaking & faculty fees$4,0003%
- Travel & lodging$3,6533%
- Food & beverage$4,6843%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk AS | 75 | $92,675 |
| Novartis | 42 | $45,747 |
| Heartflow, Inc. | 19 | $38,440 |
| Edwards Lifesciences | 12 | $15,240 |
| Janssen Global Services, LLC | 11 | $14,557 |
| Amgen | 11 | $9,781 |
| Esperion Therapeutics, Inc. | 7 | $8,257 |
| E.r. Squibb & Sons, L.L.C. | 1 | $3,600 |
| Irhythm Technologies, Inc. | 2 | $2,518 |
| Cleerly, Inc. | 3 | $343 |
| Janssen Scientific Affairs, LLC | 3 | $169 |
| Novo Nordisk | 2 | $63 |
| Johnson & Johnson | 1 | $30 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FFRct$38,409
- LEQVIO$29,101
- Edwards SAPIEN 3 Transcatheter Heart Valve$14,219
- NEXLIZET$8,000
- NEXLETOL$8,000
- Zio monitor$2,518
- ZIO XT Patch$2,518
- SAPIEN 3 Ultra RESILIA$580
- Cleerly Ischemia$272
- Cleerly Labs$272
- XARELTO$112
- ENTRESTO$103
How this compares
$231,420 in reported general payments places this provider in the 90th percentile of 2,184 cardiovascular disease providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VascepaIcosapent Ethyl | 12 | $4,285 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 12 | $2,015 |
| Rosuvastatin Calcium | 54 | $964 |
| Ezetimibe | 30 | $891 |
| Metoprolol Succinate | 48 | $641 |
| Losartan Potassium | 55 | $445 |
| Amlodipine Besylate | 40 | $299 |
| ClopidogrelClopidogrel Bisulfate | 14 | $293 |
| Atorvastatin Calcium | 30 | $285 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Stanford
- Yu-Ping WangStanford$3.8M
- Wilber SuStanford$3M
- Rajesh DashStanford$2.9M
- John CookeStanford$1.2M
- Abha KhandelwalStanford$1.1M
- Kenneth MahaffeyStanford$851K
- Ted LoveHillsborough$102.8M
- Matthew BudoffTorrance$11.3M
- Lori DanielsSan Diego$10.2M
- Paul KurthSanta Barbara$6.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.